For the latest QIDP listing, please click HERE
As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. 
Here is the break-down:
- 31 compounds with QIDP designation
- 29 antibacterials, 2 antifungals
- 22 systemically active, 9 for topical administration
- 13 in Phase 3, 9 in Phase 2, and 5 in Phase 1
- 26 from known drug classes, 5 are NCEs
[table id=10 /]
NOTE: Nabriva’s Lefamulin / BC-3781 just rec’d QIDP status and is included in the tables above. This systemic pleuromutilin has completed Phase 2 and is “ready for Phase 3”.
NOTE: Debio-1450 (the prodrug of Debio-1452 aka AFN-1252) should be added to the list. Formerly developed by Affinium, this novel FabI antibiotic is in Phase 1 development as a prodrug, and in Phase 2 as the original Debio-1452. The target of this class of fatty acid synthesis inhibitors is enoyl-acyl carrier protein reductase (ENR). The agent has a narrow spectrum of activity limited almost exclusively to staphylococci and enterococci.
NOTE: Cellceutix’ Brilacidin has been granted QIDP status Dec. 8th, 2014. This defensin-mimetic was formerly a Polymedx drug; it is being developed for ABSSSI and now in Phase 2.
